204 related articles for article (PubMed ID: 38712292)
1. CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.
Yuan X; Hao X; Chan HL; Zhao N; Pedroza DA; Liu F; Le K; Smith AJ; Calderon SJ; Lieu N; Soth MJ; Jones P; Zhang XH; Rosen JM
bioRxiv; 2024 Apr; ():. PubMed ID: 38712292
[TBL] [Abstract][Full Text] [Related]
2. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
4. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
Gou P; Zhang W
Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs.
Katavolos P; Cain G; Farman C; Romero FA; Magnuson S; Ly JQ; Choo EF; Katakam AK; Andaya R; Maher J
Toxicol Pathol; 2020 Apr; 48(3):465-480. PubMed ID: 32124659
[TBL] [Abstract][Full Text] [Related]
6. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation.
Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323
[TBL] [Abstract][Full Text] [Related]
7. CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer.
Ring A; Nguyen C; Smbatyan G; Tripathy D; Yu M; Press M; Kahn M; Lang JE
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30572639
[No Abstract] [Full Text] [Related]
8. Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles.
Hügle M; Lucas X; Ostrovskyi D; Regenass P; Gerhardt S; Einsle O; Hau M; Jung M; Breit B; Günther S; Wohlwend D
Angew Chem Int Ed Engl; 2017 Oct; 56(41):12476-12480. PubMed ID: 28766825
[TBL] [Abstract][Full Text] [Related]
9. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
10. CBP/p300 Bromodomain Inhibitor-I-CBP112 Declines Transcription of the Key ABC Transporters and Sensitizes Cancer Cells to Chemotherapy Drugs.
Strachowska M; Gronkowska K; Michlewska S; Robaszkiewicz A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572840
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation.
de Almeida Nagata DE; Chiang EY; Jhunjhunwala S; Caplazi P; Arumugam V; Modrusan Z; Chan E; Merchant M; Jin L; Arnott D; Romero FA; Magnuson S; Gascoigne KE; Grogan JL
Cell Rep; 2019 Apr; 27(1):269-281.e4. PubMed ID: 30943407
[TBL] [Abstract][Full Text] [Related]
12. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell AR; Huang H; Liao D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
[TBL] [Abstract][Full Text] [Related]
13. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
[TBL] [Abstract][Full Text] [Related]
14. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
[TBL] [Abstract][Full Text] [Related]
15. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
16. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Hammitzsch A; Tallant C; Fedorov O; O'Mahony A; Brennan PE; Hay DA; Martinez FO; Al-Mossawi MH; de Wit J; Vecellio M; Wells C; Wordsworth P; Müller S; Knapp S; Bowness P
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10768-73. PubMed ID: 26261308
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
18. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
19. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Zhou Y; Bastian IN; Long MD; Dow M; Li W; Liu T; Ngu RK; Antonucci L; Huang JY; Phung QT; Zhao XH; Banerjee S; Lin XJ; Wang H; Dang B; Choi S; Karin D; Su H; Ellisman MH; Jamieson C; Bosenberg M; Cheng Z; Haybaeck J; Kenner L; Fisch KM; Bourgon R; Hernandez G; Lill JR; Liu S; Carter H; Mellman I; Karin M; Shalapour S
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33602823
[TBL] [Abstract][Full Text] [Related]
20. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
